Bill Text: NY A01641 | 2023-2024 | General Assembly | Introduced
Bill Title: Requires health insurance policies to offer full coverage for annual testing for ovarian cancer; requires certain health care providers offer annual testing for ovarian cancer.
Spectrum: Partisan Bill (Democrat 2-0)
Status: (Introduced) 2024-01-03 - referred to insurance [A01641 Detail]
Download: New_York-2023-A01641-Introduced.html
STATE OF NEW YORK ________________________________________________________________________ 1641 2023-2024 Regular Sessions IN ASSEMBLY January 17, 2023 ___________ Introduced by M. of A. HUNTER -- read once and referred to the Committee on Insurance AN ACT to amend the insurance law, the social services law and the public health law, in relation to requiring health insurance policies to fully cover testing for ovarian cancer and requiring certain health care providers to offer annual testing for ovarian cancer The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Subsection (i) of section 3216 of the insurance law is 2 amended by adding a new paragraph 11-c to read as follows: 3 (11-c) (A) Every policy that provides coverage for hospital, surgical 4 or medical care shall offer full coverage for annual testing to patients 5 that are at high-risk of developing ovarian cancer including, but not 6 limited to, FDA-approved testing, transvaginal ultrasound, pelvic exam, 7 and other exams regardless if presenting signs and symptoms. 8 (B) Such additional coverage shall not be subject to annual deduct- 9 ibles and coinsurance but shall be borne solely by the insurer. 10 § 2. Subsection (l) of section 3221 of the insurance law is amended by 11 adding a new paragraph 11-c to read as follows: 12 (11-c) (A) Every insurer delivering a group or blanket policy or issu- 13 ing a group or blanket policy for delivery in this state that provides 14 coverage for hospital, surgical or medical care shall offer full cover- 15 age for annual testing for individuals at high-risk of developing ovari- 16 an cancer including, but not limited to, FDA-approved testing, transva- 17 ginal ultrasound, pelvic exam and other exams available to those at 18 high-risk of developing ovarian cancer regardless if presenting signs 19 and symptoms. 20 (B) Such additional coverage shall not be subject to annual deduct- 21 ibles and coinsurance but shall be borne solely by the insurer. 22 § 3. Section 4303 of the insurance law is amended by adding a new 23 subsection (p-1) to read as follows: EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD02610-01-3A. 1641 2 1 (p-1) (1) A medical expense indemnity corporation, a hospital service 2 corporation or a health service corporation that provides coverage for 3 hospital, surgical or medical care shall offer full coverage for annual 4 testing for individuals at high-risk of developing ovarian cancer 5 including, but not limited to, FDA-approved testing, transvaginal ultra- 6 sound, pelvic exam and other exams for individuals at high-risk of 7 developing ovarian cancer regardless if presenting signs or symptoms. 8 (2) Such additional coverage shall not be subject to annual deduct- 9 ibles and coinsurance but shall be borne solely by the insurer. 10 § 4. Subdivision 2 of section 365-a of the social services law is 11 amended by adding a new paragraph (iii) to read as follows: 12 (iii) annual ovarian cancer testing including, but not limited to, 13 FDA-approved testing, pelvic exam, transvaginal ultrasound and other 14 exams available to those at risk or high-risk for cancer regardless if 15 presenting signs and symptoms. 16 § 5. The public health law is amended by adding a new section 2405-a 17 to read as follows: 18 § 2405-a. Required offering of ovarian cancer testing. 1. Health care 19 providers such as a physician, physician assistant, nurse practitioner, 20 or midwife providing primary care shall ask specific questions to deter- 21 mine if there are any signs or symptoms that may indicate ovarian 22 cancer. Once signs and symptoms of ovarian cancer have been detected, or 23 a provider is suspicious the patient has ovarian cancer, ovarian cancer 24 "testing" may then be performed, which could encompass a pelvic exam, 25 FDA-approved testing, transvaginal ultrasound, and other exams for 26 ovarian cancer. Additionally, providers shall avail patients with ovari- 27 an cancer education, including, but not limited to, information on the 28 signs and symptoms of ovarian cancer and providing the patient with a 29 copy of the informational pamphlet developed and supplied by the depart- 30 ment, unless the health care practitioner providing such services 31 reasonably believes that: (a) the individual is being treated for a life 32 threatening emergency; or (b) the individual lacks capacity to consent 33 to ovarian cancer testing. 34 2. As used in this section, "primary care" means the medical fields of 35 family medicine, general pediatrics, primary care, internal medicine, 36 primary care obstetrics, or primary care gynecology, without regard to 37 board certification. 38 3. The offering of ovarian cancer testing under this section shall be 39 culturally and linguistically appropriate in accordance with rules and 40 regulations promulgated by the commissioner. 41 4. The department shall develop informational pamphlets on ovarian 42 cancer and supply such pamphlets to health service providers. 43 5. This section shall not affect the scope of practice of any health 44 care practitioner or diminish any authority or legal or professional 45 obligation of any health care practitioner to offer ovarian cancer test- 46 ing or to provide services or care for the subject of ovarian cancer 47 testing. 48 § 6. This act shall take effect on the first of January next succeed- 49 ing the date on which it shall have become a law and shall apply to 50 policies issued, reissued, renewed, modified or amended on or after such 51 date.
